Compare GLP-1 medicines
Medicines side by side
Each comparison sets two UK licensed GLP-1 medicines next to each other: active substance, maker, licence, pen or tablet, strengths, pack and NHS route. Every fact comes from the SmPC, NICE, the MHRA or the NHS.
Mounjaro vs Wegovy
Tirzepatide and semaglutide: licences, pens, needles and NICE guidance.
- Read the comparisonWegovy vs Ozempic
The same active substance under two licences, pens and strength ranges.
- Read the comparisonMounjaro vs Ozempic
Both licensed for type 2 diabetes, and Mounjaro also for weight management.
- Read the comparisonWegovy injection vs tablets
The weekly semaglutide pen and the daily tablet the MHRA approved in June 2026.
- Read the comparisonSaxenda vs Wegovy
Liraglutide once a day and semaglutide once a week, both from Novo Nordisk.
- Read the comparison
How these pages are written
The comparisons cover what the product information and the NHS guidance say. Treatment decisions belong to you and your prescriber.
Taken from the SmPC
Licences, strengths, pens and pack contents come from each summary of product characteristics on the electronic medicines compendium, quoted where the wording matters.
NICE and the MHRA
NHS routes come from NICE technology appraisals and guidelines, and licence decisions from the MHRA. Each page links to every source it uses.
No verdicts
The pages state differences. They never rank one medicine above another or say which suits anyone, because that is for the prescriber.
Dated
Each page shows the day its facts were last checked against the official pages it cites.